🧾 What This Document Is

This is a Form 8-K filing, specifically an "Exhibit 99.1" which is a press release the company wants to officially share with investors. It’s not a dry financial report, but an important update on their main drug development program. Companies use these to announce major news between their regular quarterly earnings reports.

🏢 What The Company Does

👉 In simple terms, Inhibitor Therapeutics is a small, publicly traded drug development company. They don't discover new medicines from scratch. Instead, they take existing, approved drugs and figure out new, patent-protected ways to use them for untreated diseases. Their main focus is a drug called itraconazole for a rare genetic condition.

The Disease: They are targeting Gorlin Syndrome (BCCNS), a rare inherited disorder where patients develop dozens or even hundreds of skin cancers (basal cell carcinomas) over their lifetime. This leads to constant, repeated surgeries.

Their Goal: Develop a version of the old antifungal drug itraconazole to treat these skin cancers in Gorlin Syndrome patients, aiming to reduce the need for surgery.

💊 The Clinical Trial Update

The company is running a key study in Malaysia with a partner, Avior Bio, Inc. This isn't a study to see if the drug works, but a "pharmacokinetic" (PK) study. That means they are measuring how the drug moves through the body—how it’s absorbed, distributed, and cleared.

• Why it matters: For their regulatory strategy, they need to prove their formulation behaves similarly to (or better than) the existing drug. This study is designed to be the last clinical study needed before they can apply for FDA approval.
• Timeline: They are on track. The next test doses are in April 2026. Lab analysis will follow in May, with final results expected in late May or early June 2026.

🧪 The Secret Sauce: The Formulation

This is the core of their innovation. The standard version of itraconazole doesn't dissolve well in water, leading to unpredictable absorption in the body.

👉 Inhibitor has created a proprietary "amorphous" formulation. Think of it like taking a clumpy, crystalline sugar cube and transforming it into a fine powder that dissolves instantly in your tea. This special form is designed to make the drug absorb more consistently and reliably.

The company's data shows their version has no detectable crystalline structure, proving it's in this new, more soluble form. This could lead to better and more predictable patient outcomes.

📦 The Intellectual Property (IP) Move

A huge part of a drug company's value is its patents. Inhibitor is now planning to file a new, global patent application specifically for this special amorphous formulation.

👉 This is a major strategic move. If granted, this patent would be owned entirely by Inhibitor with no royalty payments to others. It strengthens their "intellectual property estate" around the drug itself, making their program more valuable for future partnerships or commercialization.

💰 Financial & Strategic Implications

This filing isn't about quarterly revenue or profit. It's about de-risking a key program and building value.

• Progress: The clinical work is on schedule and on budget, which is good news for a small company's cash burn.
• Goal: Completing this final PK study removes a major hurdle to submitting their New Drug Application (NDA) to the FDA.
• Value: A stronger patent portfolio could make their lead program more attractive to larger pharmaceutical companies for a licensing or partnership deal, which is often how small biotechs fund final development and commercialization.

🔮 What's Next

The next 6-8 weeks are critical for getting the test results. After that:

1. They will finalize the full Clinical Study Report.
2. They will prepare and submit the NDA to the FDA.
3. They will continue discussions with potential partners for funding and commercialization, where this new patent filing adds leverage.

⚖️ Big Picture

👍 Strengths:

• Clear, focused mission on a rare disease with high unmet need.
• Innovative formulation strategy that could solve a known drug problem.
• Strategic IP expansion to protect their innovation.
• Clinical program is progressing on time and on budget.

⚠️ Risks:

• Single Program Risk: The company's value is almost entirely tied to the success of this one itraconazole program.
• Regulatory Risk: The FDA could require additional studies or have other concerns, delaying or blocking approval.
• Commercial Risk: Even if approved, the market for Gorlin Syndrome is very small. Success will depend on pricing, reimbursement, and convincing doctors to change treatment habits.

🧠 The Analogy

Imagine you have a brilliant but poorly designed key (the old drug) that works on a specific lock (the disease) but is hard to grip and turns inconsistently. Inhibitor is re-casting that same key in a new, ergonomic design (the amorphous formulation) so it works more reliably. Now, they are applying for a design patent on their new key, proving through tests that it works smoothly, with the goal of finally getting official approval to use it.

📇 Key Contacts & People

• Investor Relations Contact: Simon Bettink, VP of Operations
• Email: [email protected]
• Company Website: www.inhibitortx.com

🧩 Final Takeaway

Inhibitor Therapeutics is ticking key boxes to advance its lead drug for Gorlin Syndrome toward an FDA application. By completing the final clinical study and strengthening its patent wall around its unique formulation, the company is both de-risking its program and increasing its potential value in the eyes of partners and investors. The next few months of test results will be crucial.